Europe Prefilled Syringes Market

Market Outlook

The Europe prefilled syringes market, valued at USD 1.33 billion in 2025, is projected to reach USD 1.42 billion in 2026 and USD 2.19 billion by 2035, representing a CAGR of 4.9% during the forecast period 2026 to 2035.

To learn more about this report, request a free sample copy

Market Report: Key Takeaways

Market Size & Trends

• Therapeutic syringes currently hold the largest share by purpose, while specialty syringes are forecasted to grow at the fastest pace during the forecast period.
• Antibodies currently represent the leading and fastest-growing molecule category.
• Hematological disorders currently lead the market by therapeutic area.
• Glass syringes hold the current largest market share by barrel material, while plastic syringes are expected to grow fastest during the forecast period.
• Germany is the leading country market, while France is projected to record the highest CAGR during forecast period.

Key Market Statistics

• Market Size in 2026: $1.42 Billion
• Estimated Market Size in 2035: 2.19 Billion
• CAGR (2026-2035): 4.9%
• Germany: Largest market in 2026
• France: Projected to record the highest CAGR

Market Introduction

The Europe prefilled syringes market represents demand for ready-to-use syringe systems that combine a drug container with an administration mechanism, typically comprising a barrel, stopper, plunger rod, and either an integrated needle or a connector for a separate needle. Demand is supported by the growing use of injectable antibody therapies, anticoagulants, vaccines, specialty medicines, and treatments suitable for administration outside hospital settings. For instance, Dupixent is available in prefilled syringe and pen presentations, with trained patients or caregivers permitted to administer treatment when considered appropriate, illustrating the role of convenient injectable presentations in supporting recurring, potentially home-based treatment.

A distinction exists between prefillable and prefilled syringes. Prefillable syringes are supplied to pharmaceutical manufacturers or filling partners before drug filling, while prefilled syringes contain the finished medicinal product and are ready for administration. Sterile, ready-to-use containers supplied in nests and tubs also support automated and high-throughput filling operations. Applications span therapeutic injections, vaccination, specialty treatments, and injectable aesthetic procedures, with container requirements varying according to formulation characteristics and intended use.

Product development is increasingly focused on improving container–drug compatibility, minimizing drug-container interactions, enhancing injection performance, and accommodating sensitive or highly viscous formulations. Silicone-free glass syringes, specialized surface coatings, and polymer-based containers provide different approaches to these requirements, while purpose-specific platforms such as SCHOTT Pharma's TOPPAC cosmetic syringe demonstrate the development of application-specific solutions. Their commercial value ultimately depends on demonstrated compatibility with the formulation, filling process, sterilization requirements, and intended delivery device.

Market Segmentation

Based on the research, we have segmented the Europe prefilled syringes market by purpose of syringe, type of molecule, therapeutic area, type of barrel fabrication material, number of barrel chambers, type of needle system, usability of syringe, and countries.

• By Purpose of Syringe: Therapeutic Syringes, Specialty Syringes, and Cosmetic Syringes
• By Type of Molecule: Antibodies, Vaccines, Proteins, Small Molecules, and Other Molecules
• By Therapeutic Area: Hematological Disorders, Infectious Diseases and Other Disorders
• By Type of Barrel Fabrication Material: Glass Syringes and Plastic Syringes
• By Number of Barrel Chambers: single chamber syringes and dual chamber syringes
• By Type of Needle System: Staked Needle Syringes and Luer Syringes
• By Usability of Syringe: Disposable Syringes and Reusable Syringes
• By Countries: Germany, France, UK, Italy, Spain, and Rest of Europe

Europe Prefilled Syringes Market Key Insights

What Are the Key Drivers of Growth in the Europe Prefilled Syringes Market?

• Recurring injectable antibody treatment supports sustained demand. It also contributes to sustained demand for reliable drug-delivery systems. Repeatedly administered medicines require consistent dose delivery and convenient preparation, making prefilled syringes an attractive option when the formulation is compatible with device storage. Dupixent provides a verified example of long-term antibody therapy available in a prefilled syringe presentation.
• Infectious disease prevention expands demand beyond conventional therapeutic injections. Beyfortus, which contains the monoclonal antibody nirsevimab, is used to prevent respiratory syncytial virus (RSV) disease in eligible children. Its authorized prefilled syringe presentation illustrates that demand from infectious disease applications extends beyond vaccines to include prophylactic antibody therapies.
• Ready-to-fill supply formats support pharmaceutical manufacturing workflows. Ready-to-fill supply formats can streamline pharmaceutical manufacturing workflows by enabling manufacturers to source containers with predefined processing and packaging characteristics. Gerresheimer's syringe portfolio includes configurations designed to support filling efficiency and accommodate varying formulation requirements. This allows manufacturers to evaluate suppliers based not only on acquisition costs but also on production efficiency and overall manufacturing performance.

What are the Main Challenges for Market Growth?

• Drug–container compatibility can constrain platform selection. Formulations may interact with silicone, elastomers, glass residues, or other contact materials, affecting particles, adsorption, or protein stability. Stevanato Group highlights silicone interactions and tungsten residues as key considerations for sensitive biologics. Therefore, syringe compatibility must be assessed for each formulation.
• Shelf-life stability must be assessed alongside delivery performance. Container closure integrity alone does not ensure consistent drug delivery through the end of shelf life. Developers must also evaluate plunger performance, connection integrity, and compatibility with associated devices, making complete system assessment increasingly important.
• Changing drug presentations adds development and regulatory complexity. A vial-based medicine cannot simply be transferred to a prefilled syringe without assessing device compatibility, quality, and performance. These requirements can extend development timelines and increase the cost of introducing a new presentation.

Recent Developments in Europe Prefilled Syringes Market

• Celltrion launched Omlyclo® (omalizumab): In August 2026, Celltrion launched the 300 mg strength of Omlyclo® (omalizumab) across key European markets, including Germany, the UK and France, in both prefilled syringe and autoinjector presentations. The company plans to extend availability across additional European countries by the end of 2026.
• Samsung Bioepis launched OPUVIZ™ 40 mg/mL: In August 2026, Samsung Bioepis launched OPUVIZ™ 40 mg/mL, an aflibercept biosimilar referencing Eylea®, in a prefilled syringe across Europe. The ready-to-use single-dose presentation provides an additional administration option for ophthalmologists treating retinal diseases.
• Formycon and Klinge Biopharma: In May 2026, Formycon and Klinge Biopharma launched the aflibercept biosimilars Ahzantive® and Baiama® as prefilled syringes in the European Union. The rollout began in Germany, France and Italy, with additional Central and Eastern European markets scheduled to follow.

Industry Experts on Europe Prefilled Syringes Market

The Europe prefilled syringes market is being shaped by growing demand for drug-delivery solutions that can accommodate sensitive biologics and provide pharmaceutical manufacturers with greater flexibility in selecting container materials and formats.

Highlighting the industry's shift toward a broader range of prefillable syringe materials and technologies, Mauro Stocchi, Chief Business Officer at Stevanato Group, stated, "The addition of COP and COC pre-fillable syringes will uniquely position Stevanato Group to be able to offer both COC, COP and glass options in the market, empowering customers to select the best-suited solution to fit their needs from multiple options." He further noted that the development demonstrates Stevanato Group's focus on "meeting market needs through an integrated and comprehensive portfolio of drug delivery solutions."

• Founder and Chief Technology Officer, Mid-sized Organization, United Kingdom
• Chief Operating Officer, Very Large Organization, India
• Chief Executive Officer, Small-sized Medical Device Company
• Former Chief Commercial Officer, Large Organization, Germany
• Senior Director, Product Technology Services and Former Director, Pharmaceutical Delivery Systems Marketing, Very Large Organization, United States
• Former Head of R&D and Product Strategy, Mid-Sized Organization, Switzerland
• Senior Portfolio Director, Large Organization, United States

In addition, the market report includes transcripts of the following other third-party discussions:

• Founder, President and Chief Executive Officer; Chief Commercial Officer, Small Company, US
• Executive Director, Small Company, Canada
• President, Chief Commercial Officer, Mid-sized, US
• President and Co-founder, Small Company, US
• Director of Scientific Affairs, Large Company, US
• Senior Director of Drug Product Compliance, Large Company, South Korea
• Vice President of Global Operations; Vice President of Global Market Development, Very Large Company, US
• Head of Portfolio Strategy and Management, Small Company, US
• Senior Manager Regulatory Affairs, Very Large Company, US
• Technical Product Manager, Very Large Company, US

Market Share Insights

Which Purpose of Syringe Accounts for the Largest Share of the Europe Prefilled Syringes Market?

• Therapeutic syringes currently hold the largest share in the Europe prefilled syringes market owing to their established use in recurring treatment and anticoagulation. Inhixa, an enoxaparin medicine, provides an example of a therapeutic product supplied in prefilled syringes for specified clinical uses.
• Specialty syringes are expected to register the fastest growth during the forecast period. Application-specific requirements are driving demand for syringes with tighter control over container surfaces, delivery forces, and component tolerances, particularly in ophthalmic and sensitive biologic applications.

Which Molecule is Gaining the Most Ground in the Europe Prefilled Syringes Market?

• Antibodies are expected to hold both the largest share of the current market, reflecting the increased adoption of injectable antibody therapies, particularly products requiring repeated administration and specialized containment and rising use of long-term antibody treatments and convenient delivery formats.

Which Therapeutic Area is at the Forefront of European Prefilled Syringes Development?

• Hematological disorders hold the largest share of the current market. Established use of prefilled anticoagulants, particularly enoxaparin, supports a large and mature demand base across surgical, hospital and outpatient settings. Inhixa, for example, is an EU-authorized enoxaparin product used for venous thromboembolism prevention.
• Infectious diseases are expected to register the highest growth in the market during the forecast period. Expanding immunization and prophylaxis programs can broaden prefilled syringe use across large eligible populations, while newer antibody-based prevention products such as Beyfortus add incremental demand. Its EU-authorized presentation is available as a prefilled syringe, supporting this growth potential.

Which Barrel Fabrication Leads the Europe Prefilled Syringes Market?

• Glass Syringes hold the largest share of the current market. Their dominance is supported by established pharmaceutical use, strong compatibility with injectable formulations, and a mature supplier base offering standardized and specialized configurations. Platforms such as SCHOTT Pharma's syriQ and Stevanato Group's glass syringe systems reinforce the widespread commercial adoption of glass.
• Plastic Syringes are expected to record the fastest CAGR during the forecast period. This growth is attributed to the increasing demand for lightweight, break-resistant and design-flexible delivery systems, particularly for application-specific requirements. SCHOTT Pharma's TOPPAC platform exemplifies this trend, although formulation compatibility and storage requirements remain key selection factors.

Country-wise Analysis: Europe's Leading Prefilled Syringes Markets

Germany represents the leading country market

• Germany holds the largest share of the current market. Its position is supported by a strong pharmaceutical manufacturing base, substantial biologics and injectable-drug activity, and a well-established ecosystem spanning pharmaceutical packaging, syringe manufacturing, and fill-finish services. Companies such as SCHOTT Pharma, Gerresheimer and Vetter provide capabilities across primary containers, prefilled syringe systems, filling and packaging, strengthening Germany's role within the regional supply chain.
• France is estimated to record the fastest growth during the forecast period; this trend is supported by increasing adoption of biologics, preventive therapies, and patient-centric injectable delivery formats.

Key Players Profiled in Europe Prefilled Syringes Market

The Europe prefilled syringes market is supported by a broad base of pharmaceutical companies and specialized packaging and drug-delivery suppliers, including, SCHOTT Pharma, Gerresheimer, Stevanato Group, Vetter Pharma, and ROVI.

Report Deliverables and Customization

The report includes complimentary Excel data packs covering market landscape analysis, product competitiveness, recent developments, patent analysis, KOL analysis, SWOT analysis, and market sizing and forecast analysis. A complimentary PowerPoint presentation is available, and up to 15% customization can be requested subject to data availability.

Report Authorship

Author(s): Simriti Gupta and Pemba Lahmo. Both authors contribute to Roots Analysis's healthcare and pharma research practice.

Independence and Non-Affiliation

This report is an independent work of market research and analysis published by Roots Analysis. It is not affiliated with, sponsored by, endorsed by, or reviewed by any company, drug brand, or regulatory body referenced within this report. No content in this report should be construed as medical advice. Roots Analysis maintains its own proprietary primary research process, and does not receive compensation from any company profiled within the report, in exchange for inclusion or favorable characterization.